|
|
TABLE OF CONTENTS |
|
|
August 2017 Volume 17 Number 8 | Advertisement
|
2016 2-year Impact Factor 37.147 Journal Metrics 2-year Median 28 | In this issue Research Highlights Reviews Perspectives
| Open for Submissions
npj Precision Oncology is a new open access, online-only, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine. The journal is part of the Nature Partner Journals series and published in partnership with The Hormel Institute, University of Minnesota.
Explore the benefits of submitting your manuscript. | |
|
|
|
Advertisement |
|
|
|
|
Advertisement |
|
MEDTECH DEALMAKERS A supplement to Nature Biotechnology | Nature Medicine | Nature Reviews Drug Discovery Medtech Dealmakers explores the dealmaking strategies of the growing medical technology industry, and provides in-depth analysis of emerging technologies, as well as showcase innovative companies seeking partners. Check out the latest issue for medtech dealmaking and financing trends in 2016, and diagnostics deals from the past year- particularly for immuno oncology applications. Download the issue for FREE | | |
|
|
RESEARCH HIGHLIGHTS
| Top | Tumour vaccines: Personal training by vaccination p451 | doi:10.1038/nrc.2017.61 Two groups have shown that personalized, neoantigen-based tumour vaccines elicit effective T cell responses in patients with advanced melanoma, leading to favourable clinical outcomes. Combination with checkpoint blockade can be of additional benefit. PDF
Pancreatic cancer: iExosomes target the 'undruggable' p452 | doi:10.1038/nrc.2017.54 Kamerkar et al. have engineered exosomes that target KRASG12D (iExosomes) and have demonstrated the specificity and efficacy of iExosomes in targeting oncogenic KRAS in mouse models of pancreatic cancer. PDF
Therapeutic resistance: Transcribing patterns of resistance p452 | doi:10.1038/nrc.2017.59 Shaffer et al. analysed resistance in melanoma at the single-cell level and found that non-genetic, transcriptional variability in rare cells can predict the eventual emergence of drug resistance. PDF
Immunotherapy: Keeping breast cancer in check p454 | doi:10.1038/nrc.2017.55 Nolan et al. show that triple-negative breast cancers with BRCA1 mutations are immunogenic and susceptible to treatment with a combination of two checkpoint inhibitors and chemotherapy. PDF
Chemotherapy: Neutrophils deliver the goods p454 | doi:10.1038/nrc.2017.62 Neutrophils carrying liposomes that contain the antimitotic drug paclitaxel can penetrate the brain and suppress the recurrence of glioma in mice, thereby significantly improving survival. PDF
Neuroblastoma: Tumours get super-enhanced p455 | doi:10.1038/nrc.2017.56 Van Groningen et al. unravel the epigenetic nature of intratumoural heterogeneity in neuroblastoma, which comprises both lineage-committed adrenergic cells and undifferentiated mesenchymal cells that are defined by unique super-enhancer transcriptional networks and gene expression signatures. PDF
Epigenetics: Therapy-induced transcription is cryptically widespread p456 | doi:10.1038/nrc.2017.57 A new study demonstrates that DNA methyltransferase inhibitors and histone deacetylase inhibitors induce widespread cryptic transcription from transposable elements that may contribute to cancer immunogenicity. PDF
| IN BRIEF
| Epigenetics: Tumour suppressive HIF2α | Tumour immunology: Feeding frenzy | Tumour immunology: Tumours copy to escape | Leukaemia: Multiple origins of relapse PDF |
| | |
|
|
Advertisement |
|
An online-only, open access, multidisciplinary journal dedicated to publishing high-quality original research articles, reviews, editorials, commentaries, and hypothesis generating observations on all areas of breast cancer research. Part of the Nature Partner Journals series, published in partnership with the Breast Cancer Research Foundation.
Now open for submissions >> | | |
|
|
|
|
REVIEWS
| Top |
Microenvironmental regulation of tumour angiogenesis Michele De Palma, Daniela Biziato & Tatiana V. Petrova p457 | doi:10.1038/nrc.2017.51 This Review discusses the extrinsic regulation of angiogenesis by the tumour microenvironment, highlighting potential vulnerabilities that could be targeted to improve the applicability and reach of anti-angiogenic cancer therapies. Abstract | Full Text | PDF
|
Novel insights into mesothelioma biology and implications for therapy Timothy A. Yap, Joachim G. Aerts, Sanjay Popat & Dean A. Fennell p475 | doi:10.1038/nrc.2017.42 Our understanding of mesothelioma pathobiology has increased dramatically in the past 5 years, with an improvement in our knowledge of mesothelioma genetics, epigenetics, tumour microenvironment and immunobiology. This Review discusses these advances and how they might affect therapeutic strategies. Abstract | Full Text | PDF | Supplementary information
|
Advertisement |
|
|
|
|
|
|
PERSPECTIVES
| Top |
OPINION Fragile sites in cancer: more than meets the eye Thomas W. Glover, Thomas E. Wilson & Martin F. Arlt p489 | doi:10.1038/nrc.2017.52 This Opinion article discusses recent studies that have provided new insights into the mechanisms of common fragile site instability and the resulting genomic effects, which include the generation of focal copy number alterations that affect the genomic landscape of many cancers. Abstract | Full Text | PDF
|
VIEWPOINT Drugging the 'undruggable' cancer targets Chi V. Dang, E. Premkumar Reddy, Kevan M. Shokat & Laura Soucek p502 | doi:10.1038/nrc.2017.36 In this Viewpoint article, we asked four scientists working to target important, but so-called 'undruggable', proteins in cancer for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of cancer research. Abstract | Full Text | PDF
|
| | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | |
1 comment:
GMP manufacturing as well as catalog products for customers in industry and research area. Neoantigen
Post a Comment